- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 25.02. | Femasys Inc.: Femasys Announces Peer-Reviewed Publication of Positive Safety and Efficacy Results from FemBloc Permanent Birth Control Clinical Trials | 128 | GlobeNewswire (Europe) | --Positive data from prospective, multi-center trials confirmed compelling effectiveness and five-year safety with high satisfaction from both patients and practitioners-- ATLANTA, Feb. 25, 2025 (GLOBE... ► Artikel lesen | |
| 11.02. | Femasys gains UK approval for women's health products | 2 | Investing.com | ||
| 11.02. | Femasys erhält britische Zulassung für Produkte im Bereich Frauengesundheit | 7 | Investing.com Deutsch | ||
| FEMASYS Aktie jetzt für 0€ handeln | |||||
| 11.02. | Femasys Inc.: Femasys Announces UK Regulatory Approvals for FemaSeed for Female Infertility Treatment and Two Diagnostic Devices | 1 | GlobeNewswire (USA) | ||
| 04.02. | Femasys Inc.: Femasys Announces Israeli Regulatory Approvals for FemaSeed for Female Infertility Treatment and Two Diagnostic Devices | 117 | GlobeNewswire (Europe) | ATLANTA, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive... ► Artikel lesen | |
| 30.01. | Femasys announces notices of intention to grant for two new European patent applications | 5 | Seeking Alpha | ||
| 30.01. | Femasys Inc.: Femasys Announces Notices of Intention to Grant for Two New European Patent Applications Covering Use of FemBloc Permanent Birth Control | 158 | GlobeNewswire (Europe) | ATLANTA, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive... ► Artikel lesen | |
| 16.01. | Femasys Inc.: Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemaSeed for Female Infertility Treatment | 2 | GlobeNewswire (USA) | ||
| 27.11.24 | The Latest Analyst Ratings For Femasys | 4 | Benzinga.com | ||
| 26.11.24 | Femasys Inc.: Femasys Announces Peer-Reviewed Publication of Positive Data from Prospective, Multicenter Pivotal Trial of FemaSeed Infertility Treatment | 120 | GlobeNewswire (Europe) | ATLANTA, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office... ► Artikel lesen | |
| 12.11.24 | Femasys GAAP EPS of -$0.24, revenue of $554.91M | 1 | Seeking Alpha | ||
| 12.11.24 | Femasys Inc.: Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update | 94 | GlobeNewswire (Europe) | ATLANTA, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office... ► Artikel lesen | |
| 01.11.24 | Femasys secures new patent for FemBloc birth control | 2 | Investing.com | ||
| 01.11.24 | Femasys Inc.: Femasys Announces Issued U.S. Patent Covering FemBloc Device for Female Permanent Birth Control | 1 | GlobeNewswire (USA) | ||
| 30.10.24 | Femasys Inc.: Femasys Announces Partnership with Boston IVF, Prominent Network of Fertility Centers, to Offer FemaSeed | 1 | GlobeNewswire (USA) | ||
| 29.10.24 | FEMASYS INC - 8-K, Current Report | 2 | SEC Filings | ||
| 10.10.24 | Femasys Inc.: Femasys to Exhibit at ASRM 2024 and Participate in the Congress' KEEPR Education Program | 1 | GlobeNewswire (USA) | ||
| 02.10.24 | Femasys Inc.: Femasys Receives Second Order from Spain Partners After Successfully Completing Commercial FemaSeed® Infertility Treatments | 1 | GlobeNewswire (USA) | ||
| 18.09.24 | Femasys Inc.: Femasys Announces Infertility Clinic Customers from Coast to Coast | 4 | GlobeNewswire (USA) | ||
| 12.09.24 | H.C. Wainwright maintains Buy rating on Femasys on secureing strategic Spain distribution | 1 | Investing.com |
Seite:
1 2 Weiter >>
34 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INTUITIVE SURGICAL | 517,50 | -1,62 % | Intuitive Surgical Aktie: Das sagen aktuelle Marktberichte | Der Aktienkurs von Intuitive Surgical zeigt sich am 01. März 2025 mit einem Kurs von 552,45 EUR nahezu unverändert gegenüber dem Vortag. Trotz eines Monatsverlusts von 1,80% verzeichnet der führende... ► Artikel lesen | |
| ROKU | 78,36 | -0,58 % | Roku Reveals First OLED, but There's a Catch | ||
| ATOSSA THERAPEUTICS | 0,689 | -0,29 % | Atossa Therapeutics, Inc.: Atossa Therapeutics Responds to PTAB Ruling on U.S. Patent No. 11,572,334 and Announces the Issuance of U.S. Patent No. 12,201,591 | SEATTLE, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the prevention and treatment... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc.: Evofem Biosciences Announces Financial Results for the Third Quarter of 2024 | - Improved loss from operations by 31% -
- Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health... ► Artikel lesen | |
| QUIDELORTHO | 36,800 | 0,00 % | QuidelOrtho Corp - 8-K, Current Report | ||
| CENTENE | 54,72 | +0,11 % | Centene-Aktie legt um 2,37 Prozent zu (55,9327 €) | Der Anteilsschein von Centene notiert heute etwas fester. Der jüngste Kurs betrug 58,25 US-Dollar. Ein Kursplus von 2,37 Prozent steht gegenwärtig für die Aktie von Centene zu Buche. Die Aktie verteuerte... ► Artikel lesen | |
| VERU | 0,491 | +1,32 % | Veru Inc.: Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress | --Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint of preservation of lean mass as well as greater... ► Artikel lesen | |
| TEMPEST THERAPEUTICS | 0,747 | -1,32 % | Tempest Therapeutics: Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma | Fast Track Designation highlights potential of amezalpat to address unmet need for patients with HCC Amezalpat builds momentum with both Fast Track and Orphan Drug Designations BRISBANE, Calif.... ► Artikel lesen | |
| NANO-X IMAGING | 6,400 | 0,00 % | Nano-X Imaging LTD.: Nanox.ARC Imaging System Receives CE Mark, Expanding Medical Imaging Offering in European Market | CE Mark is the first major regulatory milestone for Nanox.ARC Imaging System in the European market; follows recent general use FDA clearance in the U.S.New clinical data supporting use of Nanox.ARC... ► Artikel lesen | |
| FULGENT GENETICS | 15,400 | -0,65 % | Piper Sandler Has Lowered Expectations for Fulgent Genetics (NASDAQ:FLGT) Stock Price | ||
| LANTHEUS | 93,56 | +0,47 % | Lantheus Holdings-Direktor verkauft Aktien im Wert von 5 Millionen US-Dollar | ||
| PERSPECTIVE THERAPEUTICS | 2,300 | -3,36 % | Perspective Therapeutics, Inc. - 8-K, Current Report | ||
| AMN HEALTHCARE SERVICES | 24,000 | -1,64 % | AMN Healthcare Services Inc. Q4 Earnings Summary | WASHINGTON (dpa-AFX) - Below are the earnings highlights for AMN Healthcare Services Inc. (AMN):Earnings: -$187.53 million in Q4 vs. $12.49 million in the same period last year.
EPS: -$4.90... ► Artikel lesen | |
| OMNICELL | 35,600 | +1,14 % | Omnicell Gains 41.6% in a Year: What's Driving the Stock? | ||
| ALPHATEC | 10,700 | -1,83 % | Alphatec Holdings, Inc. - 8-K, Current Report |
FEMASYS INC gehört der Branche Gesundheitswesen an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 1,565 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu FEMASYS INC finden Sie auf Wallstreet Online.
